Omar Ali

Dr. Omar Ali

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 1997 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
KDKirk D. Denicoff
Kirk D. Denicoff
ESEarlian E. Smith-Jackson
Earlian E. Smith-Jackson
EDElizabeth R. Disney
Elizabeth R. Disney
OAOmar Ali
Omar Ali
GLGabriele S. Leverich
Gabriele S. Leverich
RPRobert M. Post
Robert M. Post
We compared the prophylactic efficacy of lithium, carbamazepine, and the combination and identified possible clinical markers of response. Fifty-two outpatients who met DSM-III-R criteria for bipolar illness were randomly assigned in a double-blind design for an intended 1 year of treatment with lithium or carbamazepine, a crossover to the opposite drug in the second year, and then a third year on the combination. Patients received monthly detailed evaluations, and daily life chart ratings of the degree of functional incapacity associated with mania or depression were completed. For evaluable patients: 13 (31.0%) of 42 failed to complete a full year of lithium therapy owing to lack of efficacy, and 2 dropped out because of side effects; 13 (37.1%) of 35 withdrew from carbamazepine within the first year owing to lack of efficacy, and 10 dropped out because of side effects (9 of the 10 had a rash); 7 (24.1%) of 29 withdrew from the combination therapy owing to lack of efficacy. The percentage of the evaluable patients who had marked or moderate improvement on the Clinical Global Impressions scale was 33.3% on lithium. 31.4% on carbamazepine, and 55.2% on the combination treatment, which was not significantly different. By a variety of measures, lithium was more effective than carbamazepine in the prophylaxis of mania. Patients with a past history of rapid cycling did poorly on monotherapy (28.0% responded to lithium; 19.0% responded to carbamazepine), but significantly better on the combination (56.3%, p < .05). These prospective, randomized data suggest a high incidence of inadequate response to either mood stabilizer or their combination despite use of adjunctive agents as needed. Additional novel treatment regimens are needed to better decrease affective morbidity in large numbers of bipolar outpatients.

1 October 2006 in Psychology of Music
Verified
Journal Article
Closed access
PDF file
OAOmar Ali
Omar Ali
ZPZehra F. Peynircioğlu
Zehra F. Peynircioğlu
We explored the role of lyrics and melodies in conveying emotions in songs. Participants rated the intensity of four types of emotions in instrumental music or the same music paired with lyrics. Melodies and lyrics conveyed the same intended emotion in Experiments 1 and 3 but were mismatched in Experiments 2 and 4. The major findings in Experiments 1 and 2 were that lyrics detracted from the emotion in happy and calm music (positive emotions), but enhanced the emotion in sad and angry music (negative emotions). In all cases, melodies of songs were more dominant than the lyrics in eliciting emotions. In addition, in Experiments 3 and 4, the emotion in the songs appeared to transfer, simply by association, to pictures of common objects arbitrarily paired with the songs.

1 September 2002 in NeuroImage
Verified
Journal Article
Closed access
JDJean-Claude Dreher
Jean-Claude Dreher
EKEtienne Koechlin
Etienne Koechlin
OAOmar Ali
Omar Ali
JGJordan Grafman
Jordan Grafman

1 May 2019 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
OAOmar Ali
Omar Ali
XYX.Q. Yu
X.Q. Yu
GRG.J. Robbie
G.J. Robbie
YWY. Wu
Y. Wu
KSK. Shoemaker
K. Shoemaker
HJH.S. Jafri
H.S. Jafri
MEDI3902 is a bivalent, bispecific human immunoglobulin G1κ monoclonal antibody that binds to both the Pseudomonas aeruginosa PcrV protein involved in host cell cytotoxicity and the Psl exopolysaccharide involved in P. aeruginosa colonization and tissue adherence. MEDI3902 is being developed for the prevention of nosocomial P. aeruginosa pneumonia in high-risk patients. This phase 1 dose-escalation study (NCT02255760) evaluated the safety, pharmacokinetics, antidrug antibody (ADA) responses and ex vivo anticytotoxicity and opsonophagocytic killing activities of MEDI3902 after a single intravenous infusion in healthy adults aged 18 to 60 years. Fifty-six subjects were randomized in a 3:1 ratio to receive 250, 750, 1500 or 3000 mg of MEDI3902 or placebo and followed for 60 days afterwards. Treatment-emergent adverse events (TEAEs) were mild or moderate in severity; no serious TEAEs were observed. The most common TEAEs were infusion-related reactions. MEDI3902 exhibited approximately linear pharmacokinetics across the 250, 750 and 1500 mg doses and nonlinear pharmacokinetics between the 1500 and 3000 mg doses. One subject in the 3000 mg group tested positive for ADA on day 61 and had a lower MEDI3902 serum concentration from days 43 to 61 than ADA-negative subjects. Serum anticytotoxicity antibody concentrations and opsonophagocytic killing activity were correlated with MEDI3902 serum concentrations across all doses. Phase 1 study results of MEDI3902 in healthy subjects support further evaluation of its safety and efficacy in subjects at risk for P. aeruginosa pneumonia.

1 November 1999 in Journal of Affective Disorders
Verified
Journal Article
Closed access
KDKirk D. Denicoff
Kirk D. Denicoff
OAOmar Ali
Omar Ali
AMAllan F. Mirsky
Allan F. Mirsky
ESEarlian E. Smith-Jackson
Earlian E. Smith-Jackson
GLGabriele S. Leverich
Gabriele S. Leverich
RPRobert M. Post
Robert M. Post

1 October 2006 in Journal of Speech, Language, and Hearing Research
Verified
Journal Article
Closed access
PDF file
OAOmar Ali
Omar Ali
MTMichael Thomassen
Michael Thomassen
GSGERALYN SCHULZ
GERALYN SCHULZ
LHLara A. Hosey
Lara A. Hosey
MVMary Varga
Mary Varga
ABAllen R. Braun
Allen R. Braun
Speech-related changes in regional cerebral blood flow (rCBF) were measured using H215O positron-emission tomography in 9 adults with adductor spasmodic dysphonia (ADSD) before and after botulinum toxin (BTX) injection and 10 age- and gender-matched volunteers without neurological disorders. Scans were acquired at rest and during production of continuous narrative speech and whispered speech. Speech was recorded during scan acquisition for offline quantification of voice breaks, pitch breaks, and percentage aperiodicity to assess correlations between treatment-related changes in rCBF and clinical improvement. Results demonstrated that speech-related responses in heteromodal sensory areas were significantly reduced in persons with ADSD, compared with volunteers, before the administration of BTX. Three to 4 weeks after BTX injection, speech-related responses were significantly augmented in these regions and in left hemisphere motor areas commonly associated with oral-laryngeal motor control. This pattern of responses was most strongly correlated with the objective measures of clinical improvement (decreases in the frequency of voice breaks, pitch breaks, and percentage aperiodicity). These data suggest a pathophysiological model for ADSD in which BTX treatment results in more efficient cortical processing of sensory information, making this information available to motor areas that use it to more effectively regulate laryngeal movements.